Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00465959 | Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease | PHASE1 | COMPLETED | 24 | — | — | Apr 1, 2007 | Jun 1, 2007 | Dec 27, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 400 mg TrIP | EXPERIMENTAL | - |
| 800 mg TrIP | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| trospium chloride inhalation powder (TrIP) | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male or female COPD patients between the ages of 40 and 80 years * Smoking history of at least 10 pack years * Not currently using (or able to wash out of) any long acting bronchodilators Exclusion Criteria: * Candidate on a waiting list for surgery while on study * Using lo...